Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Alto Neuroscience GAAP EPS of -$0.62 | 1 | Seeking Alpha | ||
Di | Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 50 | Business Wire | MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric... ► Artikel lesen | |
Di | Alto Neuroscience, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
Di | Alto Neuroscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
25.10. | FY2028 EPS Forecast for Alto Neuroscience Lowered by Analyst | 2 | MarketBeat | ||
23.10. | Alto Neuroscience's Depression Trial Failure Sends Shares Into Downward Spiral | 5 | MedCity News | ||
23.10. | Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform | 1 | Benzinga.com | ||
23.10. | Alto Neuroscience stock downgraded by Rodman & Renshaw on trial miss, PT slashed | 2 | Investing.com | ||
ALTO NEUROSCIENCE Aktie jetzt für 0€ handeln | |||||
23.10. | Alto Neuroscience shares PT slashed by Baird following ALTO-100 failure | 1 | Investing.com | ||
23.10. | Baird senkt Kursziel für Alto Neuroscience-Aktien nach ALTO-100-Misserfolg | 3 | Investing.com Deutsch | ||
23.10. | Alto Neuroscience (NYSE:ANRO) Stock Rating Lowered by Rodman & Renshaw | 2 | MarketBeat | ||
22.10. | Alto Neuroscience stock craters 57% post-market on failed study | 4 | Seeking Alpha | ||
22.10. | Alto Neuroscience reports setback in depression drug trial | 4 | Investing.com | ||
22.10. | After-hours movers: McDonald's, Starbucks, Seagate, Alto Neuroscience and more | 25 | Investing.com | ||
22.10. | Alto Neuroscience meldet Rückschlag bei Studie zu Depressionsmedikament | 4 | Investing.com Deutsch | ||
22.10. | Alto Neuroscience, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
10.09. | Alto Neuroscience stock gets Buy rating amid trial optimism | 4 | Investing.com | ||
09.09. | Alto Neuroscience maintains Buy rating with $32 target | 1 | Investing.com | ||
14.08. | Alto Neuroscience GAAP EPS of -$0.60 | 1 | Seeking Alpha | ||
13.08. | Alto Neuroscience, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 105,30 | -0,28 % | Vidac Pharma, BioNTech, Bayer - Milliardenmarkt Gentherapien lockt Investoren | In der Pharmabranche zeichnen sich zwei Trends ab: zum einen die personalisierte Medizin, die Therapien auf das genetische Profil einzelner Patienten zuschneidet, zum anderen entwickeln Unternehmen... ► Artikel lesen | |
CUREVAC | 2,552 | -1,85 % | EQS-News: CureVac veröffentlicht am 12. November 2024 Finanzergebnisse des dritten Quartals sowie der ersten neun Monate 2024 und informiert über seine Geschäftsentwicklung | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Quartalsergebnis
CureVac veröffentlicht am 12. November 2024 Finanzergebnisse des dritten Quartals sowie der ersten neun Monate... ► Artikel lesen | |
AMGEN | 282,00 | -1,23 % | Amgen Aktie: Stabilität und Wachstum geboten! | Der Biotechnologiekonzern Amgen verzeichnete eine bemerkenswerte Wendung an der Börse, nachdem Bedenken hinsichtlich seines experimentellen Medikaments zur Gewichtsreduktion, MariTide, ausgeräumt wurden.... ► Artikel lesen | |
NOVAVAX | 7,338 | -0,19 % | Novavax Inc. Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Novavax Inc. (NVAX) released Loss for third quarter that decreased from last year and beat the Street estimates.The company's bottom line totaled -$121.30 million, or... ► Artikel lesen | |
BIOGEN | 157,75 | +0,51 % | Biogen Inc.: Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease | TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
MAINZ BIOMED | 0,235 | 0,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung zur Entwicklung von Darmkrebsfrüherkennungstest der nächsten Generation für den globalen Markt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Kooperation
Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung zur Entwicklung von Darmkrebsfrüherkennungstest... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 14,700 | -3,67 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress | Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy; on... ► Artikel lesen | |
VIKING THERAPEUTICS | 52,96 | +1,61 % | Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly? | ||
BIOCRYST PHARMACEUTICALS | 7,470 | +3,18 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
CARDIOL THERAPEUTICS | 1,808 | +0,22 % | Cardiol Therapeutics Inc: Cardiol Therapeutics joins PRISM Emerging Biotech Index | ||
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,787 | -4,90 % | Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 106,65 | +0,14 % | Sparked by FDA expansion, Sarepta's Elevidys takes another leap in sales | ||
EXELIXIS | 33,610 | +0,87 % | Exelixis, Inc.: Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November | - Presentations to be webcast on www.exelixis.com
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences... ► Artikel lesen | |
VAXART | 0,601 | -10,71 % | Vaxart Inc reports results for the quarter ended September 30 - Earnings Summary | ||
EXACT SCIENCES | 48,700 | +1,41 % | Exact Sciences meldet Fortschritte bei der Früherkennung von Krebs |